Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...

MSD in the Philippines’ “Di Mo DeCERV!” campaign has been awarded Bronze in the Advocacy category at this year’s ICE Awards, ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its headquarters in Rahway, New Jersey. Confirmation of that has come in the form ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Correction: This script has been updated ...